FLT3-ITD阳性急性髓系白血病诱导和巩固治疗期间抗真菌预防:ALLG AMLM16试验报告
该研究为随机双盲试验的IFD分析,94例初诊FLT3-ITD阳性AML患者在诱导和巩固期接受脂质体两性霉素B预防(5 mg/kg每周两次),索拉非尼组与安慰剂组IFD总发生率为4.3%(4/94),两组分别为3.1%(2/64)和6.7%(2/30),索拉非尼未增加IFD风险。
要点
- 脂质体两性霉素B(5 mg/kg每周两次)可用于唑类禁忌或不耐受AML患者的真菌预防。
- 索拉非尼组与安慰剂组IFD发生率分别为3.1%和6.7%,未见索拉非尼增加IFD风险。
- 诱导期共报告4例IFD(1例确诊、3例可能),总体发生率4.3%。
核心结论
- 脂质体两性霉素B联合或不联合后续唑类预防,可作为唑类禁忌或不耐受的AML患者的替代真菌预防方案。
- 索拉非尼似乎不增加侵袭性真菌病(IFD)风险。
研究设计与样本
- 随机双盲试验(ALLG AMLM16)的IFD分析,纳入94例初诊FLT3-ITD阳性成人AML患者。
- 诱导和巩固期两治疗组均接受脂质体两性霉素B 5 mg/kg每周两次预防,索拉非尼/安慰剂治疗结束后允许按机构实践改用其他预防。
主要发现
- 94例可分析患者中,诱导期报告4例IFD(1例确诊、3例可能)。
- 确诊/可能/可能IFD总发生率为4.3%(4/94),索拉非尼组3.1%(2/64),安慰剂组6.7%(2/30)。
- 7例发生输注相关反应,其中4例报告与脂质体两性霉素B给药相关。
关键数值与推荐
- 脂质体两性霉素B预防剂量为5 mg/kg,每周两次,用于诱导和巩固期。
- IFD包括确诊、可能和可能病例,由严重不良事件或不良事件报告后裁定。
临床怎么用
- 对于唑类禁忌或不耐受的FLT3-ITD阳性AML患者,可考虑脂质体两性霉素B(5 mg/kg每周两次)作为真菌预防。
- 索拉非尼治疗期间无需因IFD风险增加而调整抗真菌预防策略。
局限性
- IFD分析样本量较小(94例),事件数少(4例)。
- 原文未报告统计比较或P值,无法判断组间差异是否具有统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To report the rates of proven, probable and possible invasive fungal disease (IFD) in patients receiving antifungal prophylaxis during initial induction and consolidation treatment of acute myeloid leukaemia (AML) plus either sorafenib or placebo. METHODS: As part of a randomized, double-blind trial of sorafenib or placebo in combination with intensive chemotherapy for newly diagnosed adult patients with FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD)-positive AML (ALLG AMLM16 trial), liposomal amphotericin B (LAMB) prophylaxis was administered at 5 mg/kg twice weekly during induction and consolidation phases in both sorafenib and placebo treatment arms. Alternative prophylaxis was allowed per institutional practice once sorafenib/placebo treatment was completed. IFD episodes, reported as either a serious adverse event or an adverse event, were adjudicated. RESULTS: Of the 94 patients included for analysis of IFD, four IFD episodes (one proven and three possible) were reported during the induction treatment phase. The overall rate of proven/probable/possible IFD was 4.3% (4/94), with rates of 3.1% (2/64) and 6.7% (2/30) in the sorafenib and placebo groups, respectively. Seven patients had infusion-related reactions, and four were reported to be associated with LAMB administration. CONCLUSIONS: LAMB with or without subsequent azole prophylaxis could be an alternative option for fungal prophylaxis for patients with AML in whom azoles are contraindicated or not tolerated. Sorafenib does not appear to be associated with an increased risk of IFD.
引用
- Neoh CF, Yong MK, Rowley L, et al. Antifungal prophylaxis in patients with FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD)-positive acute myeloid leukaemia receiving sorafenib during initial induction and consolidation treatment in ALLG AMLM16 trial. J Antimicrob Chemother. 2025. PMID: 41133432. doi:10.1093/jac/dkaf385
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。